ITS
InsiderTrading
TradesInsidersCompaniesCluster BuysRankingsAbout
ITS
InsiderTrading Screener

Track SEC Form 4 insider trades. See what corporate insiders are buying and selling.

Browse

  • Trades
  • Insiders
  • Companies
  • Cluster Buys
  • Rankings

Top Insiders

  • Mark Zuckerberg
  • Elon Musk
  • Jamie Dimon
  • Satya Nadella
  • Lisa Su
  • Jensen Huang

Screeners

  • CEO & CFO Purchases
  • Director Purchases
  • Top Buys This Week
  • Top Sales This Week
  • 10b5-1 Trades
  • Buy/Sell Ratios
  • Politician Overlap
  • Sectors

Learn

  • Learn
  • What is a Form 4?
  • About & Methodology
  • What are Cluster Buys?
  • Top Insider Rankings
  • Privacy Policy
  • Terms of Use

Data

  • SEC EDGAR Form 4 ↗
  • CongressStock.com ↗
  • Track13F.com ↗
  • About the data
© 2026 InsiderTradingScreener.com. Data from SEC EDGAR Form 4 filings.For informational purposes only. Not financial advice.
Home / Trades / #492709

GILLIS JONATHAN sold MPLT

July 17, 2026 · Form 4 insider transaction

GILLIS JONATHAN sold 16,969 shares of MapLight Therapeutics, Inc. at $37.61 per share, a transaction worth $638.2K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 3 days after the transaction.

Direction
Disposed (sell-side)
Shares
16,969
Price
$37.61
Total value
$638.2K
InsiderGILLIS JONATHAN
RoleOfficer
CompanyMapLight Therapeutics, Inc. (MPLT)
SecurityVoting Common Stock
Transaction codeS — Open-market sale
Transaction dateJuly 17, 2026
Filing dateJuly 20, 2026
Shares owned after145,140
OwnershipDirect
10b5-1 planYes
AmendedNo

Footnotes

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.; The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

View the original Form 4 on SEC EDGAR